Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder
- PMID: 28335622
- PMCID: PMC5453828
- DOI: 10.1176/appi.ajp.2016.16050518
Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder
Erratum in
-
CORRECTIONS.Am J Psychiatry. 2017 Jun 1;174(6):604. doi: 10.1176/appi.ajp.2017.1746correction3. Am J Psychiatry. 2017. PMID: 28565951 No abstract available.
Abstract
Objective: The purpose of this article was to inform the first-line treatment choice between cognitive-behavioral therapy (CBT) or an antidepressant medication for treatment-naive adults with major depressive disorder by defining a neuroimaging biomarker that differentially identifies the outcomes of remission and treatment failure to these interventions.
Method: Functional MRI resting-state functional connectivity analyses using a bilateral subcallosal cingulate cortex (SCC) seed was applied to 122 patients from the Prediction of Remission to Individual and Combined Treatments (PReDICT) study who completed 12 weeks of randomized treatment with CBT or antidepressant medication. Of the 122 participants, 58 achieved remission (Hamilton Depression Rating Scale [HAM-D] score ≤7 at weeks 10 and 12), and 24 had treatment failure (<30% decrease from baseline in HAM-D score). A 2×2 analysis of variance using voxel-wise subsampling permutation tests compared the interaction of treatment and outcome. Receiver operating characteristic curves constructed using brain connectivity measures were used to determine possible classification rates for differential treatment outcomes.
Results: The resting-state functional connectivity of the following three regions with the SCC was differentially associated with outcomes of remission and treatment failure to CBT and antidepressant medication and survived application of the subsample permutation tests: the left anterior ventrolateral prefrontal cortex/insula, the dorsal midbrain, and the left ventromedial prefrontal cortex. Using the summed SCC functional connectivity scores for these three regions, overall classification rates of 72%-78% for remission and 75%-89% for treatment failure was demonstrated. Positive summed functional connectivity was associated with remission with CBT and treatment failure with medication, whereas negative summed functional connectivity scores were associated with remission to medication and treatment failure with CBT.
Conclusions: Imaging-based depression subtypes defined using resting-state functional connectivity differentially identified an individual's probability of remission or treatment failure with first-line treatment options for major depression. This biomarker should be explored in future research through prospective testing and as a component of multivariate treatment prediction models.
Trial registration: ClinicalTrials.gov NCT00360399.
Keywords: Antidepressants; Biological Markers; Brain Imaging Techniques; Cognitive Therapy.
Figures
Comment in
-
Getting Personalized: Brain Scan Biomarkers for Guiding Depression Interventions.Am J Psychiatry. 2017 Jun 1;174(6):503-505. doi: 10.1176/appi.ajp.2017.17030314. Am J Psychiatry. 2017. PMID: 28565957 No abstract available.
References
-
- Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for depression. Neuropsychopharmacol. 2004;29:1765–1781. - PubMed
-
- American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3. Arlington, VA: American Psychiatric Association; 2010.
-
- Craighead WE, Dunlop BW. Combination psychotherapy and antidepressant medication for depression: For whom, when and how. Ann Rev Psychol. 2014;65:267–300. - PubMed
-
- Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, Thase ME, Trivedi MH, Keller MB. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry. 2005;62:513–520. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
